FDA grants RPDD to ReviR’s RTX-117 for CMT

RegulatoryRTX-117Positive

AI Analysis

Summary

ReviR Therapeutics received Rare Pediatric Disease Designation from the FDA for RTX-117, an oral small-molecule investigational therapy for CMT (Charcot-Marie-Tooth disease). This regulatory recognition may provide incentives including priority review and market exclusivity extensions.

Outcome Details

Rare Pediatric Disease Designation granted

Importance:6/10

Sentiment:

0.70

RPDDFDArare diseasesmall moleculeoral therapy

Read the original article

Published by Pharmaceutical Technology on August 27, 2026 10:36 AM

Read Original